Grafa News and Videos — Page 235

Kodiak Sciences (NASDAQ:KOD) reported that Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial evaluating treatments for wet age-related macular degeneration.

Codexis (NASDAQ:CDXS) signed an agreement with an unnamed siRNA drug developer to explore stereo-defined fragment synthesis using its ECO Synthesis platform.

National Healthcare Properties (NYSE:NHP) agreed to sell 40 outpatient medical facilities for approximately $531 million, with closing expected in the fourth quarter of 2026.

MediciNova (NASDAQ:MNOV) reported topline results from a Phase 2 placebo-controlled trial evaluating MN-001, also known as tipelukast, in patients with type 2 diabetes, fatty liver disease, and elevated triglycerides.

Gray Media (NYSE:GTN) raised its third-quarter 2026 political advertising revenue guidance to $188 million–$195 million, compared with its previous forecast of $165 million–$185 million.

Zymeworks (NASDAQ:ZYME) completed its acquisition of Theravance Biopharma for $17 per share, adding rights to YUPELRI profit sharing and international royalties.

Hudbay Minerals (NYSE:HBM) extended the reserve mine life of its Snow Lake operations in Manitoba to 2043 under an updated plan that increases projected gold production.

IDEAYA Biosciences (NASDAQ:IDYA) promoted Dr. Michael White from chief scientific officer to president of research and development, effective September 28, 2026.

U.S.-listed gold miners fell in premarket trading as spot gold prices declined 3.2% to $4,149.89 per ounce, reaching their lowest level since August 5.

NVIDIA (NASDAQ:NVDA) introduced its Open Agent Safety Platform, an open-source framework designed to provide controls for AI agents through runtime monitoring and policy enforcement tools.